US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience

2.31

+0.01000.43%

Post-market: 2.380.0700+3.03%18:45 EDT

Volume:2.62M

Turnover:6.07M

Market Cap:62.54M

PE:-0.99

High:2.49

Open:2.32

Low:2.29

Close:2.30

Loading ...

Overview Company News Filings

Alto Neuroscience Inc. Unveils Presentation on Precision Medicine Advancements in Psychiatry

JonesTrading Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

Optimistic Buy Rating for Alto Neuroscience Amid Promising ALTO-203 Developments and Strategic Opportunities

Alto Neuroscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Alto Neuroscience Reports Positive Phase 2 Trial Results

Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results From Exploratory Phase 2 Proof-of-Concept Trial of Alto-203

THOMSON REUTERS

Alto Neuroscience Inc - Alto-203 Well Tolerated With Insomnia as Most Frequent Adverse Event

THOMSON REUTERS

Alto Neuroscience Unveils Precision Medicine Strategy for Psychiatry in New Corporate Presentation

Promising Future for Alto Neuroscience: Strategic Acquisition and Strong Financial Position Drive Buy Rating

Buy Rating for Alto Neuroscience Driven by Strategic Acquisitions and Promising Pipeline Developments

Alto Neuroscience’s Strategic Acquisition and Promising Pipeline Boost Buy Rating

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc.

Alto Neuroscience acquires dopamine agonist combination candidate

Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression

Alto Neuroscience Inc - Chase Therapeutics Eligible for up to $71.5 Mln in Milestone Payments

THOMSON REUTERS

Alto Neuroscience Inc - Phase 2B Trial for Alto-207 Expected by Mid-2026

THOMSON REUTERS

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

THOMSON REUTERS

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ANRO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":2.31,"timestamp":1751054400000,"preClose":2.3,"halted":0,"volume":2615672,"hourTrading":{"tag":"盘后","latestPrice":2.38,"preClose":2.31,"latestTime":"18:45 EDT","volume":619244,"amount":1430640.0652,"timestamp":1751064355324},"delay":0,"floatShares":17903521,"shares":27072129,"eps":-2.343213,"marketStatus":"Market Closed","change":0.01,"latestTime":"06-27 16:00:00 EDT","open":2.32,"high":2.49,"low":2.29,"amount":6070855.1757896,"amplitude":0.086957,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.343213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":2.3,"preHourTrading":{"tag":"盘前","latestPrice":2.39,"preClose":2.295,"latestTime":"09:29 EDT","volume":120,"amount":282.800016,"timestamp":1751030955833},"postHourTrading":{"tag":"盘后","latestPrice":2.38,"preClose":2.31,"latestTime":"18:45 EDT","volume":619244,"amount":1430640.0652,"timestamp":1751064355324},"volumeRatio":5.889914146833553,"impliedVol":0.8007,"impliedVolPercentile":0.0361},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":17903521,"roa":"-22.88%","roe":"-38.04%","lyrEps":-2.496992,"volumeRatio":5.889914146833553,"shares":27072129,"dividePrice":0,"high":2.49,"amplitude":0.086957,"preClose":2.3,"low":2.29,"week52Low":1.6,"pbRate":"0.45","week52High":17.55,"institutionHeld":0,"latestPrice":2.31,"eps":-2.343213,"divideRate":0,"volume":2615672,"delay":0,"ttmEps":-2.343213,"open":2.32,"prevYearClose":4.23,"prevWeekClose":2.25,"prevMonthClose":2.58,"prevQuarterClose":2.16,"fiveDayClose":2.25,"twentyDayClose":2.69,"sixtyDayClose":2.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546729515","title":"Alto Neuroscience Inc. Unveils Presentation on Precision Medicine Advancements in Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2546729515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546729515?lang=en_us&edition=fundamental","pubTime":"2025-06-28 03:56","pubTimestamp":1751054198,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc., listed on NYSE under the ticker ANRO, has released a corporate presentation detailing its advancements in precision medicine for the brain. The company is focused on leveraging predictive biomarkers and target specificity to enhance clinical outcomes in central nervous system  disorders. Alto Neuroscience is progressing with a clinical-stage portfolio, having dosed over 800 patients with its novel product candidates. The company anticipates multiple phase 2 data readouts in the next two years and highlights its expected cash runway. Alto positions CNS as the next frontier in precision medicine, alongside fields like oncology and cardiovascular health. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL5mr12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2546749613","title":"JonesTrading Reaffirms Their Buy Rating on Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546749613","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546749613?lang=en_us&edition=fundamental","pubTime":"2025-06-27 21:15","pubTimestamp":1751030117,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target of $13.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2546756829","title":"Optimistic Buy Rating for Alto Neuroscience Amid Promising ALTO-203 Developments and Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2546756829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546756829?lang=en_us&edition=fundamental","pubTime":"2025-06-27 02:45","pubTimestamp":1750963514,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on ANRO stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-alto-neuroscience-amid-promising-alto-203-developments-and-strategic-opportunities-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-alto-neuroscience-amid-promising-alto-203-developments-and-strategic-opportunities-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","ALTO"],"gpt_icon":0},{"id":"2546300547","title":"Alto Neuroscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2546300547","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546300547?lang=en_us&edition=fundamental","pubTime":"2025-06-27 00:26","pubTimestamp":1750955160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 12:26 ET (16:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2546780988","title":"Alto Neuroscience Reports Positive Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2546780988","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546780988?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:54","pubTimestamp":1750938867,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has issued an announcement. On June 26, 2025, Alto Neuroscience announced positive pharmacodynamic results from...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-reports-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-reports-positive-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2546358787","title":"Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2546358787","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546358787?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:33","pubTimestamp":1750937601,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL1FrZ35:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2546878427","title":"Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results From Exploratory Phase 2 Proof-of-Concept Trial of Alto-203","url":"https://stock-news.laohu8.com/highlight/detail?id=2546878427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546878427?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:33","pubTimestamp":1750937580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUABNKWCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2546840787","title":"Alto Neuroscience Inc - Alto-203 Well Tolerated With Insomnia as Most Frequent Adverse Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2546840787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546840787?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:33","pubTimestamp":1750937580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUABNKWCH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2543680664","title":"Alto Neuroscience Unveils Precision Medicine Strategy for Psychiatry in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2543680664","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543680664?lang=en_us&edition=fundamental","pubTime":"2025-06-13 21:41","pubTimestamp":1749822118,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has released a corporate presentation detailing its progress in the field of precision medicine for the brain. The presentation highlights Alto's clinical-stage precision medicine portfolio, which aims to redefine psychiatry by using neurobiology to develop personalized medicines. With over 800 patients dosed across studies, Alto is advancing its novel product candidates and precision approach. The presentation also notes the company's focus on CNS as the next frontier in precision medicine, drawing parallels with advancements in oncology and cardiovascular fields. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL5kWSyZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2542437418","title":"Promising Future for Alto Neuroscience: Strategic Acquisition and Strong Financial Position Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2542437418","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542437418?lang=en_us&edition=fundamental","pubTime":"2025-06-11 13:55","pubTimestamp":1749621316,"startTime":"0","endTime":"0","summary":"Jefferies analyst Andrew Tsai maintained a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) on June 9 and set a price target of $15.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-future-for-alto-neuroscience-strategic-acquisition-and-strong-financial-position-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-future-for-alto-neuroscience-strategic-acquisition-and-strong-financial-position-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2541631878","title":"Buy Rating for Alto Neuroscience Driven by Strategic Acquisitions and Promising Pipeline Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2541631878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541631878?lang=en_us&edition=fundamental","pubTime":"2025-06-06 21:35","pubTimestamp":1749216922,"startTime":"0","endTime":"0","summary":"Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report). The associated price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-alto-neuroscience-driven-by-strategic-acquisitions-and-promising-pipeline-developments-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-alto-neuroscience-driven-by-strategic-acquisitions-and-promising-pipeline-developments-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540085326","title":"Alto Neuroscience’s Strategic Acquisition and Promising Pipeline Boost Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2540085326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540085326?lang=en_us&edition=fundamental","pubTime":"2025-06-04 08:05","pubTimestamp":1748995513,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on ANRO stock, giving a Buy rating yesterday. Myles Minter has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alto-neurosciences-strategic-acquisition-and-promising-pipeline-boost-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alto-neurosciences-strategic-acquisition-and-promising-pipeline-boost-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540709879","title":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2540709879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540709879?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:42","pubTimestamp":1748972559,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL6N3S60GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WWD","GH","LU1978683503.SGD","XOM","KYMR","NEM","OSK","LU1064131342.USD","BK4015","FDX","ANRO","BEAM","LU2290526834.HKD","DVN","LU2125154778.USD","VG","LU1988902786.USD","IE00BGHQF524.EUR","SIG","FCX","DG","LU2211817866.USD","BMBL","IE00BD4GTW91.USD","HPE","LU2286300806.USD","STRK","LU0985489474.SGD","PINS","CVX","STR","AGEN","SG9999001143.SGD","XYZ","LU1951198990.SGD","SCCO","LIF"],"gpt_icon":1},{"id":"2540570834","title":"Strategic Acquisition and Promising Clinical Developments Drive Buy Rating for Alto Neuroscience, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2540570834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540570834?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:35","pubTimestamp":1748961312,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-promising-clinical-developments-drive-buy-rating-for-alto-neuroscience-inc-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-promising-clinical-developments-drive-buy-rating-for-alto-neuroscience-inc-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2540778113","title":"Alto Neuroscience acquires dopamine agonist combination candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2540778113","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540778113?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:10","pubTimestamp":1748945430,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) entered into an asset purchase agreement with Chase Therapeutics for a portfolio of potentially best-in-class dopamine ago...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-acquires-dopamine-agonist-combination-candidate-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-acquires-dopamine-agonist-combination-candidate-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540094720","title":"Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2540094720","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540094720?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748945002,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation. This includes ALTO-207, formerly known as CTC-501, aimed at treating treatment-resistant depression . The acquisition aligns with Alto's mission to innovate in psychiatry by advancing ALTO-207, which combines pramipexole and ondansetron to deliver rapid antidepressant effects while minimizing adverse events. Alto plans to leverage its proprietary insights on dopamine biomarkers to further develop this promising treatment, with a Phase 2b trial anticipated by mid-2026. The transaction supports Alto's strategic expansion without altering its cash runway guidance into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLtgrWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540720090","title":"Alto Neuroscience Inc - Chase Therapeutics Eligible for up to $71.5 Mln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2540720090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540720090?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540720012","title":"Alto Neuroscience Inc - Phase 2B Trial for Alto-207 Expected by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2540720012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540720012?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2540209097","title":"Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2540209097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540209097?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748944980,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA6RF3ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2539295647","title":"Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295647","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295647?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:03","pubTimestamp":1748520180,"startTime":"0","endTime":"0","summary":"– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection –。– Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose –。MOUNTAIN VIEW, Calif., May 29, 2025----Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology  Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-presents-data-2025-120300913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LFT","BK4110","BK4107","BK4007","BK4138","BK4109","ALTO","ANRO","AFG","BK4117"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-06-27","current":-0.985485,"percent":0.945619,"low":-16.978804,"twenty":-9.980084,"median":-2.492642,"eighty":-1.263991,"high":-0.793245,"avg":-5.203863,"sd":4.111365,"marketCap":62265896},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-02","current":-1.079695,"twenty":-10.421079,"median":-6.037568,"eighty":-1.742706,"marketCap":66326716},{"date":"2025-05-09","current":-0.965115,"twenty":-10.40924,"median":-5.975847,"eighty":-1.645994,"marketCap":59287962},{"date":"2025-05-16","current":-1.041186,"twenty":-10.323409,"median":-5.766106,"eighty":-1.583083,"marketCap":65785273},{"date":"2025-05-23","current":-1.255422,"twenty":-10.270134,"median":-5.686944,"eighty":-1.500455,"marketCap":79321337},{"date":"2025-05-30","current":-1.152589,"twenty":-10.199102,"median":-5.617282,"eighty":-1.480737,"marketCap":72824027},{"date":"2025-06-06","current":-1.019763,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"marketCap":64431667},{"date":"2025-06-13","current":-1.049756,"twenty":-10.02004,"median":-5.30697,"eighty":-1.408438,"marketCap":66326716},{"date":"2025-06-20","current":-0.972631,"twenty":-9.987484,"median":-5.077305,"eighty":-1.322054,"marketCap":61453732},{"date":"2025-06-27","current":-0.985485,"twenty":-9.980084,"median":-2.492642,"eighty":-1.263991,"marketCap":62265896}],"updateTime":1751201240895}}}